This is a news story, published by Morningstar | Empowering Investor Success, that relates primarily to The Drug Enforcement Administration news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Morningstar | Empowering Investor Success, you can click here:
more news from Morningstar | Empowering Investor SuccessOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Cannabis stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug scheduling issues news, Cannabis news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Schedule III drugsMorningstar | Empowering Investor Success
•77% Informative
Cannabis stocks rose Tuesday on top of larger advances in the previous session as the government window closed for public feedback on proposed changes.
The Drug Enforcement Administration has proposed a Schedule III classification for cannabis, down from its listing on Schedule I of the federal Controlled Substances Act .
Cannabis stocks on Monday posted big gains as the 11:59 pm ET deadline loomed for comments on the rescheduling.
VR Score
85
Informative language
89
Neutral language
70
Article tone
formal
Language
English
Language complexity
53
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links